



SDI Review Form 1.6

Journal Name:	Asian Journal of Biochemistry, Genetics and Molecular Biology
Manuscript Number:	Ms_AJBGMB_49084
Title of the Manuscript:	Cytotoxicity of N-(P-chlorophenyl)-7-hydroxycoumarin-3-yl carboxamide and Ethyl 7-hydroxycoumarin-3-yl ester
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>Authors have provided an extensive introduction regarding various aspects of related to the anticancer properties of coumarins. However they did not elaborate why an ester and amide derivative of coumarin were chosen for their study. The compound numbering is problematic, according to the Scheme 1 the comp 1 is 2,4-dihydroxybenzaldehyde and comp-2 is the ester whereas in the text, Table 1, Fig. 1-3 different numbering has been used. Please address this issue.</p> <p>The experimental procedure for the preparation of both the compounds along with their spectral data must be included.</p> <p>It is desirable to include data of a reference compound e.g. doxorubicin included in Table 1.</p> <p>Table 1: the unit i.e. µg/ml is missing.</p>	<p>I have chosen these two compounds because they are new derivatives of coumarin and presence of halogen in amide compound increase the activity of the compound in addition with coumarin activity.</p> <p>I Will correct the text, Table 1 and figures 5-8 according to Scheme 1.</p> <p>OK, I Will add the spectral data of the synthesized compounds.</p> <p>OK, I Will add the reference compound-doxorubicin- in Table 1.</p> <p>OK, I will add the unite µg/ml in table 1.</p>
Minor REVISION comments	<p>Please mention if comp-2 is also known.</p> <p>Fig 1-3: the X and Y axis should be defined properly.</p>	<p>OK, I will modify the text according to Scheme 1.</p> <p>OK, I will define them.</p>
Optional/General comments	The comp-1 is known and that turned out to be the most active compound.	Yes

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	NO